Director/PDMR Shareholding

28 December 2017 14:00 GMT

TRANSACTION BY PERSON DISCHARGING MANAGERIAL

RESPONSIBILITIES - AMENDMENT

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that the notification made in accordance with the requirements of the EU Market Abuse Regulation on 15 December 2017 relating to a change in the beneficial interest in the Company's Ordinary Shares of US$0.25 each of Mr Soriot has been amended, as set out in the revised notification below.

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Pascal Soriot
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Amendment - Previous notification reference number: 00031829 - Effective date of transfer amended from 13 December 2017 - Number of shares transferred amended from 40,148
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Identification code Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b) Nature of the transaction Gift of shares to family members for nil consideration
c) Price(s) and volume(s) Price(s) Volume(s)
0 39,648
d) Aggregated information - Aggregated volume - Price Not applicable - single transaction
e) Date of the transaction 27 December 2017
f) Place of the transaction Outside a trading venue

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Gonzalo Viña UK/Global +44 203 749 5916
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology; Other +1 240 477 3771
Christer Gruvris Brilinta; Diabetes +44 203 749 5711
Nick Stone Respiratory; Renal +44 203 749 5716
US toll free +1 866 381 7277

Adrian Kemp Company Secretary

AstraZeneca PLC

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links